{
    "Trade/Device Name(s)": [
        "BD Phoenix\u2122M Automated Microbiology System - Linezolid 0.25-16 \u03bcg/mL",
        "BD Phoenix\u2122 Automated Microbiology System Linezolid (0.25-16 \u03bcg/mL) - Streptococcus ID/AST or AST",
        "BD Phoenix\u2122 Automated Microbiology System for use with the antimicrobial agent linezolid (0.25-16 \u03bcg/mL) - Streptococcus ID/AST or AST only Phoenix Panels"
    ],
    "Submitter Information": "Becton, Dickinson and Company",
    "510(k) Number": "K051266",
    "Predicate Device Reference 510(k) Number(s)": [
        "N50510",
        "K020321",
        "K020323",
        "K020322"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LON"
    ],
    "Summary Letter Date": "July 5, 2005",
    "Summary Letter Received Date": "May 16, 2005",
    "Submission Date": "May 12, 2005",
    "Regulation Number(s)": [
        "21 CFR 866.1645"
    ],
    "Regulation Name(s)": [
        "Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility Devices"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Linezolid"
    ],
    "Specimen Type(s)": [
        "Pure culture isolates of Gram-positive and Gram-negative bacteria"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BD Phoenix\u2122M Automated Microbiology System",
        "BD Phoenix instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Broth-based microdilution",
        "Automated susceptibility testing",
        "Redox indicator detection"
    ],
    "Methodologies": [
        "Antimicrobial susceptibility testing",
        "Minimal inhibitory concentration determination"
    ],
    "Submission Type(s)": [
        "System",
        "Panel",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for BD Phoenix\u2122M Automated Microbiology System with Linezolid for Streptococcus ID/AST or AST only panels",
    "Indications for Use Summary": "Intended for rapid in vitro quantitative determination of antimicrobial susceptibility by MIC of most Gram-negative aerobic and facultative anaerobic bacteria and most Gram-positive isolates including Enterobacteriaceae, Non-Enterobacteriaceae, Staphylococcus, Enterococcus, and Streptococcus, including the addition of linezolid (0.25-16 \u03bcg/mL) to Streptococcus panels.",
    "fda_folder": "Microbiology"
}